Alive in 2025 (1.10.2025) Save

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

1. Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/evaTc8Ag5Y
2. Post hoc study of Hidradenitis suppurativa (HS) phase 3 study w/ 588 pts rx w/ either PBO or adalimumab. 79% had elevated CRP. High CRP assoc w/ more severe HS, higher BMI (34 vs 28; P < .001), & lower odds of ADA response (OR 0.53). Activity or Obesity? https://t.co/ZQzumtW2LV
3. Spanish registry ARTESER, looked at GCA outcomes from 2013 to 2019. In 1200 GCA pts ~ 2 yrs F/U, The 5-Yr mortality 37.9/1000 pt/yrs; higher in males vs females (59 vs 29 p<0.001), but was same as gen population . Incr mortality w/ age & male sex. HA & Hgb were protective… https://t.co/idnuUL9Kog
4. Retrospectively review of 165 #EGPA pts, GI manifestations were assoc w/ Eosinophils > 19.5%, weight loss, & myalgia; & included abdominal pain (78%), diarrhea (40%), N/V (33%); GI hemorrhage (27%), ulcers (17%), obstruction (10%), & pancreatitis (6%) https://t.co/EzsGcFs2l2
5. Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22
6. In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/Ul4HZ1hzS0
7. Italian study of 458 #RA pts shows 16% (71)meeting the EULAR criteria for difficult 2 Rx RA ( D2T-RA); unrelated to age, gender, seropositivity. BUT D2T-RA was assoc w/ erosions (24% vs 11%), obesity (33% vs 19%) & FM (25% vs 10%) https://t.co/w5mliNkfBT
8. Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4
9. Post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8
10. Metanalysis of 5063 SLE patients, found fibromyalgia (FM) 15.8% (high heterogeneity I2- 98%). SLE pts had a 3.7 fold higher risk of FM. FM in SLE was a confounder in assessing disease activity and treatment response. FM is a frequent comorbidity in SLE https://t.co/0fSIl480PG
11. JAK inhibitors are effective at repigmentation in vitiligo. 5 RCTs, 1,550 pts showed >50% improvement (TVASI50; RR 2.67) or >75% (FVASI75; RR 3.97_ JAKi increased skin AE, but not significantly different from placebo pts. https://t.co/zIreYlUyLt
12. 12 mos study of RCT 179 gout pts starting allopurinol finds that betw mos 6-12, gout flares went down. 38% had no flares, 19% had 1 flare, & 43% had >1 flare in 2nd 6 mos. # flares equates to control and impact of gout on outcomes.
13. https://t.co/TMwXZStbJU
14. Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.… https://t.co/NsGUGvb5L5
15. Does Colchicine Lower Gout Mortality Risk? 
16. GLP-1 Agonists Alleviate Knee Osteoarthritis 
17. Prevalence of Autoimmune Diseases in the United States 
18. RheumNow Live 2025 - Join us Feb 8-9 in Dallas.